目的介绍R软件HSROC程序包联合Rev Man 5软件实现基于HSROC模型的诊断准确性试验Meta分析。方法通过对实例中的数据采用R软件HSROC程序包来拟合HSROC模型,采用Rev Man 5软件进行Meta分析。结果通过R软件HSROC程序包联合Rev Man 5软件能...目的介绍R软件HSROC程序包联合Rev Man 5软件实现基于HSROC模型的诊断准确性试验Meta分析。方法通过对实例中的数据采用R软件HSROC程序包来拟合HSROC模型,采用Rev Man 5软件进行Meta分析。结果通过R软件HSROC程序包联合Rev Man 5软件能够进行相关统计学计算及HSROC曲线的绘制,制作完整的诊断准确性试验Meta分析。结论 R软件HSROC程序包联合Rev Man 5软件可以作为系统评价制作者处理诊断准确性试验Meta分析的一种方法,可以弥补其他软件的不足之处。展开更多
Introduction:Acute respiratory infections are continuously emerging.COV-SARS-2,its variants and most viral respiratory diseases currently do not have a definitive cure.Objective:This study aims to evaluate the potenti...Introduction:Acute respiratory infections are continuously emerging.COV-SARS-2,its variants and most viral respiratory diseases currently do not have a definitive cure.Objective:This study aims to evaluate the potential therapeutic effectiveness of ginseng-based medicines for the prevention and control of acute respiratory illness,including SARS-COV-2,among the adult population.Method:We performed a systematic literature review using PubMed,Scopus,Web of Science,and Cochrane trial library for studies published between January 2000 and September 2021.Repeated search was done in Decem-ber 2023.All related clinical trials that reported the use of ginseng in COVID-19 patients and respiratory viral infections among adults were included in this analysis.Two independent researchers performed the screening.Meta-analysis was performed using Cochrane’s review manager(RevMan)version 5.4.Results:A total of 596 articles were retrieved.After screening,5 articles with RCT outcomes relevant to the review were selected for the quantitative evaluation.Ginseng was found to be effective in reducing the infection risk by over 40%,and the infected had 37.1%less severe infection,13%less feverish and a 3.4-day faster recovery from acute respiratory illness(ARI),in ginseng group compared to the placebo.Conclusion:The present study revealed that ginseng-based medicines were effective in reducing the acute respi-ratory illness(ARI)infection risk by over 40%and when infected,the ginseng dosed group recovered 3.4 days faster than the placebo group.In addition,ginseng lessened the severity and fever from the infection compared to the placebo group.展开更多
旨在系统评价我国健康猪源大肠杆菌对四环素类药物耐药性的情况,为养殖业合理用药决策提供依据。计算机搜索PubMed、Web of science、SinoMed、CNKI等10个数据库。应用Revman 5.3软件进行Meta分析,并对各研究间异质性进行评价。共纳入2...旨在系统评价我国健康猪源大肠杆菌对四环素类药物耐药性的情况,为养殖业合理用药决策提供依据。计算机搜索PubMed、Web of science、SinoMed、CNKI等10个数据库。应用Revman 5.3软件进行Meta分析,并对各研究间异质性进行评价。共纳入20篇符合条件的研究,共4343株分离自健康猪源的大肠杆菌。对大肠杆菌四环素类药物耐药率进行单组率Meta分析结果显示,耐药率由高到低依次是:土霉素97.0%,其95%置信区间(CI)为90.4%~99.1%;金霉素94.7%,95%CI为91.9%~97.5%;四环素93.5%,95%CI为90.8%~95.4%;强力霉素74.4%,95%CI为58.5%~85.7%;地美环素70.6%,95%CI为63.1%~77.2%;替加环素34.2%,95%CI为31.0%~37.5%;米诺环素33.2%,95%置信区间CI为3.9%~62.4%。对亚组分析结果显示:从地区上看,四环素耐药率从高到低依次是华北99.3%、华中95.1%、华北与华中94.1%、华东92.8%、华南88.6%、西南88.4%、东北87.3%;从省份来看,除西藏自治区为40.5%外,其余10省分组都超过80%;强力霉素耐药率从高到低依次是华北98.4%、华中78.1%、西南76.6%、华南68.3%、华东61.1%;从时间上看,四环素耐药率在2005至2010、2011至2015、2016至2020的3个时间段分别为94.5%、92.3%、96.3%,强力霉素耐药率在2011至2015、2016至2020的2个时间段分别为74.4%、75.7%。结果提示,中国地区健康猪源大肠杆菌对四环素类药物普遍耐药。研究设计、地区差异、使用时间长短、饲养模式等是异质性存在的主要原因。展开更多
文摘目的介绍R软件HSROC程序包联合Rev Man 5软件实现基于HSROC模型的诊断准确性试验Meta分析。方法通过对实例中的数据采用R软件HSROC程序包来拟合HSROC模型,采用Rev Man 5软件进行Meta分析。结果通过R软件HSROC程序包联合Rev Man 5软件能够进行相关统计学计算及HSROC曲线的绘制,制作完整的诊断准确性试验Meta分析。结论 R软件HSROC程序包联合Rev Man 5软件可以作为系统评价制作者处理诊断准确性试验Meta分析的一种方法,可以弥补其他软件的不足之处。
文摘Introduction:Acute respiratory infections are continuously emerging.COV-SARS-2,its variants and most viral respiratory diseases currently do not have a definitive cure.Objective:This study aims to evaluate the potential therapeutic effectiveness of ginseng-based medicines for the prevention and control of acute respiratory illness,including SARS-COV-2,among the adult population.Method:We performed a systematic literature review using PubMed,Scopus,Web of Science,and Cochrane trial library for studies published between January 2000 and September 2021.Repeated search was done in Decem-ber 2023.All related clinical trials that reported the use of ginseng in COVID-19 patients and respiratory viral infections among adults were included in this analysis.Two independent researchers performed the screening.Meta-analysis was performed using Cochrane’s review manager(RevMan)version 5.4.Results:A total of 596 articles were retrieved.After screening,5 articles with RCT outcomes relevant to the review were selected for the quantitative evaluation.Ginseng was found to be effective in reducing the infection risk by over 40%,and the infected had 37.1%less severe infection,13%less feverish and a 3.4-day faster recovery from acute respiratory illness(ARI),in ginseng group compared to the placebo.Conclusion:The present study revealed that ginseng-based medicines were effective in reducing the acute respi-ratory illness(ARI)infection risk by over 40%and when infected,the ginseng dosed group recovered 3.4 days faster than the placebo group.In addition,ginseng lessened the severity and fever from the infection compared to the placebo group.
文摘旨在系统评价我国健康猪源大肠杆菌对四环素类药物耐药性的情况,为养殖业合理用药决策提供依据。计算机搜索PubMed、Web of science、SinoMed、CNKI等10个数据库。应用Revman 5.3软件进行Meta分析,并对各研究间异质性进行评价。共纳入20篇符合条件的研究,共4343株分离自健康猪源的大肠杆菌。对大肠杆菌四环素类药物耐药率进行单组率Meta分析结果显示,耐药率由高到低依次是:土霉素97.0%,其95%置信区间(CI)为90.4%~99.1%;金霉素94.7%,95%CI为91.9%~97.5%;四环素93.5%,95%CI为90.8%~95.4%;强力霉素74.4%,95%CI为58.5%~85.7%;地美环素70.6%,95%CI为63.1%~77.2%;替加环素34.2%,95%CI为31.0%~37.5%;米诺环素33.2%,95%置信区间CI为3.9%~62.4%。对亚组分析结果显示:从地区上看,四环素耐药率从高到低依次是华北99.3%、华中95.1%、华北与华中94.1%、华东92.8%、华南88.6%、西南88.4%、东北87.3%;从省份来看,除西藏自治区为40.5%外,其余10省分组都超过80%;强力霉素耐药率从高到低依次是华北98.4%、华中78.1%、西南76.6%、华南68.3%、华东61.1%;从时间上看,四环素耐药率在2005至2010、2011至2015、2016至2020的3个时间段分别为94.5%、92.3%、96.3%,强力霉素耐药率在2011至2015、2016至2020的2个时间段分别为74.4%、75.7%。结果提示,中国地区健康猪源大肠杆菌对四环素类药物普遍耐药。研究设计、地区差异、使用时间长短、饲养模式等是异质性存在的主要原因。
